Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 58 of 242 for:    furosemide

Measurement of Kidney Blood Flow and Oxygen Levels by MRI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01318967
Recruitment Status : Completed
First Posted : March 21, 2011
Results First Posted : April 10, 2015
Last Update Posted : September 7, 2018
Sponsor:
Information provided by (Responsible Party):
Wake Forest University Health Sciences ( Wake Forest University )

Study Type Interventional
Study Design Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Diagnostic
Condition Chronic Kidney Disease
Interventions Drug: Furosemide
Other: Placebo
Enrollment 10
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Furosemide
Hide Arm/Group Description

With and without furosemide

Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.

Period Title: Overall Study
Started 10
Completed 10
Not Completed 0
Arm/Group Title Furosemide
Hide Arm/Group Description

With and without furosemide

Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.

Overall Number of Baseline Participants 10
Hide Baseline Analysis Population Description
[Not Specified]
Age, Categorical  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 10 participants
<=18 years
0
   0.0%
Between 18 and 65 years
8
  80.0%
>=65 years
2
  20.0%
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 10 participants
Female
6
  60.0%
Male
4
  40.0%
Region of Enrollment  
Measure Type: Number
Unit of measure:  Participants
United States Number Analyzed 10 participants
10
1.Primary Outcome
Title Measurement of Renal Blood Flow of the Kidney by the PAH Method
Hide Description Renal blood flow is estimated by the PAH method.
Time Frame Renal blood flow is estimated over 1 hour by PAH
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Furosemide
Hide Arm/Group Description:

With and without furosemide

Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.

Renal blood flow is measured by PAH method and by MRI method

Overall Number of Participants Analyzed 10
Mean (Full Range)
Unit of Measure: ml/min
190
(47 to 342)
2.Secondary Outcome
Title Measurement of Regional Blood Oxygenation by MRI
Hide Description Estimate of renal blood flow by using MRI scans before and after the administration of furosemide
Time Frame One measure after furosemide (day 1)
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title MRI After Furosemide
Hide Arm/Group Description:

After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow

Furosemide: Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.

Overall Number of Participants Analyzed 10
Mean (Full Range)
Unit of Measure: ml/min
300
(69 to 620)
Time Frame [Not Specified]
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Furosemide
Hide Arm/Group Description

With and without furosemide

Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.

All-Cause Mortality
Furosemide
Affected / at Risk (%)
Total   --/-- 
Show Serious Adverse Events Hide Serious Adverse Events
Furosemide
Affected / at Risk (%)
Total   0/10 (0.00%) 
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 0%
Furosemide
Affected / at Risk (%)
Total   0/10 (0.00%) 
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Michael Rocco, MD
Organization: Wake Forest School of Medicine
Phone: 336-716-4650
EMail: mrocco@wfubmc.edu
Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences ( Wake Forest University )
ClinicalTrials.gov Identifier: NCT01318967     History of Changes
Other Study ID Numbers: IRB00010832
First Submitted: March 18, 2011
First Posted: March 21, 2011
Results First Submitted: December 8, 2014
Results First Posted: April 10, 2015
Last Update Posted: September 7, 2018